122 related articles for article (PubMed ID: 37715313)
41. [Incidence and clinical significance of platelet transfusion refractoriness after allogeneic hematopoietic stem cell transplantation in patients with chronic myelomonocytic leukemia].
Zhao C; Zhao XS; Wang Y; Yan CH; Xu LP; Zhang XH; Liu KY; Huang XJ; Sun YQ
Zhonghua Xue Ye Xue Za Zhi; 2022 Sep; 43(9):738-744. PubMed ID: 36709167
[No Abstract] [Full Text] [Related]
42. Patients With Therapy-Related CMML Have Shorter Median Overall Survival Than Those With De Novo CMML: Mayo Clinic Long-Term Follow-Up Experience.
Subari S; Patnaik M; Alfakara D; Gangat N; Elliott M; Hogan W; Litzow M; Al-Kali A
Clin Lymphoma Myeloma Leuk; 2015 Sep; 15(9):546-9. PubMed ID: 26189785
[TBL] [Abstract][Full Text] [Related]
43. Chronic myelomonocytic leukemia treated with 5-azacytidine - results from the Hellenic 5-Azacytidine Registry: proposal of a new risk stratification system.
Diamantopoulos PT; Kotsianidis I; Symeonidis A; Pappa V; Galanopoulos A; Gogos D; Karakatsanis S; Papadaki H; Palla A; Hatzimichael E; Dimou M; Papageorgiou S; Delimpasis S; Papaioannou M; Papoutselis M; Kourakli A; Tsokanas D; Anagnostopoulos A; Kontos CK; Panayiotidis P; Viniou NA;
Leuk Lymphoma; 2019 Jul; 60(7):1721-1730. PubMed ID: 30424699
[TBL] [Abstract][Full Text] [Related]
44. Clinical significance of CSF3R, SRSF2 and SETBP1 mutations in chronic neutrophilic leukemia and chronic myelomonocytic leukemia.
Ouyang Y; Qiao C; Chen Y; Zhang SJ
Oncotarget; 2017 Mar; 8(13):20834-20841. PubMed ID: 28209919
[TBL] [Abstract][Full Text] [Related]
45. [Karyotypic analysis and prognosis for 41 patients with chronic myelomonocytic leukemia].
Lu Y; Yu MX; Mu QT; Wang Q; Chen ZM; Lou JY; Jin J
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2013 Apr; 30(2):134-7. PubMed ID: 23568720
[TBL] [Abstract][Full Text] [Related]
46. Vasculitis associated with myelodysplastic syndrome and chronic myelomonocytic leukemia: French multicenter case-control study.
Roupie AL; Guedon A; Terrier B; Lahuna C; Jachiet V; Regent A; de Boysson H; Carrat F; Seguier J; Terriou L; Versini M; Queyrel V; Groh M; Benhamou Y; Maurier F; Ledoult E; Clech LL; D'Aveni M; Rossignol J; Galland J; Willems L; Chiche NJ; Peterlin P; Roux-Sauvat M; Parcelier A; Wemeau M; Lambert M; Belizna C; Puechal X; Swiader L; Cohen-Valensi R; Noc V; Dao E; Thepot S; de Frémont GM; Tanguy-Schmidt A; Koka AM; Bussone G; Philipponnet C; Konate A; Cavaille G; Guilpain P; Allain JS; Broner J; Solary E; Ruivard M; de Renzis B; Corm S; Baati N; Schleinitz N; Ponsoye M; Stamatoullas-Bastard A; Ades L; Dellal A; Tchirkov A; Aouba A; Fenaux P; Fain O; Mekinian A;
Semin Arthritis Rheum; 2020 Oct; 50(5):879-884. PubMed ID: 32896704
[TBL] [Abstract][Full Text] [Related]
47. Cytogenetic risk stratification may predict allogeneic hematopoietic stem cell transplantation outcomes for chronic myelomonocytic leukemia.
Motohashi K; Fujisawa S; Doki N; Kobayashi T; Mori T; Usuki K; Tanaka M; Fujiwara S; Kako S; Aoyama Y; Onoda M; Yano S; Gotoh M; Kanamori H; Takahashi S; Okamoto S;
Leuk Lymphoma; 2018 Jun; 59(6):1332-1337. PubMed ID: 29032731
[TBL] [Abstract][Full Text] [Related]
48. A retrospective study of cladribine and low-dose cytarabine-based regimens for the treatment of chronic myelomonocytic leukemia and secondary acute myeloid leukemia.
Bazinet A; Darbaniyan F; Kadia TM; Venugopal S; Kanagal-Shamanna R; DiNardo CD; Borthakur G; Jabbour EJ; Daver NG; Pemmaraju N; Konopleva MY; Ravandi F; Sasaki K; Chien KS; Hammond D; Pierce SA; Kantarjian HM; Garcia-Manero G; Montalban-Bravo G
Cancer; 2023 Feb; 129(4):560-568. PubMed ID: 36458426
[TBL] [Abstract][Full Text] [Related]
49. Chronic myelomonocytic leukemia masquerading as cutaneous indeterminate dendritic cell tumor: Expanding the spectrum of skin lesions in chronic myelomonocytic leukemia.
Loghavi S; Curry JL; Garcia-Manero G; Patel KP; Xu J; Khoury JD; Torres-Cabala CA; Nagarajan P; Aung PP; Gibson BR; Goodwin BP; Kelly BC; Korivi BR; Medeiros LJ; Prieto VG; Kantarjian HM; Bueso-Ramos CE; Tetzlaff MT
J Cutan Pathol; 2017 Dec; 44(12):1075-1079. PubMed ID: 28885734
[TBL] [Abstract][Full Text] [Related]
50. Utility of JAK2 V617F allelic burden in distinguishing chronic myelomonocytic Leukemia from Primary myelofibrosis with monocytosis.
Hu Z; Ramos CEB; Medeiros LJ; Zhao C; Yin CC; Li S; Hu S; Wang W; Thakral B; Xu J; Verstovsek S; Lin P
Hum Pathol; 2019 Mar; 85():290-298. PubMed ID: 30447300
[TBL] [Abstract][Full Text] [Related]
51. [Allogeneic hematopoietic stem cell transplantation for chronic myelomonocytic leukemia and juvenile myelomonocytic leukemia].
Shao Q; Wang ZD; Zheng XL; Dong L; Han DM; Yan HM; Wang HX; Duan LN
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Aug; 22(4):1058-62. PubMed ID: 25130828
[TBL] [Abstract][Full Text] [Related]
52. Targeted deep sequencing improves outcome stratification in chronic myelomonocytic leukemia with low risk cytogenetic features.
Palomo L; Garcia O; Arnan M; Xicoy B; Fuster F; Cabezón M; Coll R; Ademà V; Grau J; Jiménez MJ; Pomares H; Marcé S; Mallo M; Millá F; Alonso E; Sureda A; Gallardo D; Feliu E; Ribera JM; Solé F; Zamora L
Oncotarget; 2016 Aug; 7(35):57021-57035. PubMed ID: 27486981
[TBL] [Abstract][Full Text] [Related]
53. Targeted ex vivo reduction of CD64-positive monocytes in chronic myelomonocytic leukemia and acute myelomonocytic leukemia using human granzyme B-based cytolytic fusion proteins.
Schiffer S; Rosinke R; Jost E; Hehmann-Titt G; Huhn M; Melmer G; Barth S; Thepen T
Int J Cancer; 2014 Sep; 135(6):1497-508. PubMed ID: 24523193
[TBL] [Abstract][Full Text] [Related]
54. Impacts of graft-versus-host disease on outcomes after allogeneic hematopoietic stem cell transplantation for chronic myelomonocytic leukemia: A nationwide retrospective study.
Itonaga H; Iwanaga M; Aoki K; Aoki J; Ishiyama K; Ishikawa T; Sakura T; Fukuda T; Najima Y; Yujiri T; Mori T; Kurokawa M; Nawa Y; Uchida N; Morishita Y; Hashimoto H; Eto T; Hirokawa M; Morishima Y; Nagamura-Inoue T; Atsuta Y; Miyazaki Y
Leuk Res; 2016 Feb; 41():48-55. PubMed ID: 26754557
[TBL] [Abstract][Full Text] [Related]
55. [Decitabine-based conditioning regimen is feasible and effective in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia].
Zhao XL; Jiang EL; Zhai WH; Ma QL; Pang AM; Wei JL; He Y; Yang DL; Feng SZ; Han MZ
Zhonghua Xue Ye Xue Za Zhi; 2019 Jun; 40(6):467-471. PubMed ID: 31340618
[No Abstract] [Full Text] [Related]
56. Racial differences in the presentation and outcomes of chronic lymphocytic leukemia and variants in the United States.
Shenoy PJ; Malik N; Sinha R; Nooka A; Nastoupil LJ; Smith M; Flowers CR
Clin Lymphoma Myeloma Leuk; 2011 Dec; 11(6):498-506. PubMed ID: 21889433
[TBL] [Abstract][Full Text] [Related]
57. The 2016 WHO versus 2008 WHO Criteria for the Diagnosis of Chronic Myelomonocytic Leukemia.
Moon Y; Kim MH; Kim HR; Ahn JY; Huh J; Huh JY; Han JH; Park JS; Cho SR
Ann Lab Med; 2018 Sep; 38(5):481-483. PubMed ID: 29797820
[TBL] [Abstract][Full Text] [Related]
58. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs.
Rollison DE; Howlader N; Smith MT; Strom SS; Merritt WD; Ries LA; Edwards BK; List AF
Blood; 2008 Jul; 112(1):45-52. PubMed ID: 18443215
[TBL] [Abstract][Full Text] [Related]
59. Chronic Myelomonocytic Leukemia With Fibrosis Is a Distinct Disease Subset With Myeloproliferative Features and Frequent JAK2 p.V617F Mutations.
Gur HD; Loghavi S; Garcia-Manero G; Routbort M; Kanagal-Shamanna R; Quesada A; Khogeer H; Pierce S; Medeiros LJ; Kantarjian H; Khoury JD
Am J Surg Pathol; 2018 Jun; 42(6):799-806. PubMed ID: 29596070
[TBL] [Abstract][Full Text] [Related]
60. Treatment options and survival in real life during the past three decades in patients with chronic myelomonocytic leukemia.
Reiser J; Geissler K
Wien Med Wochenschr; 2023 Feb; 173(1-2):34-40. PubMed ID: 36282401
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
